Semaglutide

Semaglutide, developed by Novo Nordisk, is a next-generation GLP-1 (glucagon-like peptide-1) analog, derived from the basic structure of liraglutide but designed as a long-acting formulation. This innovative drug offers superior efficacy in the treatment of type 2 diabetes, improving patient outcomes with better blood glucose control and enhanced weight management.

Semaglutide has undergone extensive clinical development, with Novo Nordisk completing six Phase III clinical trials for the injectable form of semaglutide. On December 5, 2016, the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the weekly injection version of semaglutide, while a Marketing Authorization Application (MAA) was also submitted to the European Medicines Agency (EMA). In addition, the oral formulation of semaglutide, taken once daily, is currently in Phase III clinical trials.

As a long-acting GLP-1 receptor agonist, Semaglutide offers better therapeutic outcomes than liraglutide, making it a promising treatment option for patients with type 2 diabetes.

CAS No: 910463-68-2

>>Download COA

Application:

• Diabetes Treatment: Enhances glucose control and insulin sensitivity in patients with type 2 diabetes.
• Weight Management: Supports weight loss by reducing appetite and improving metabolic function.
• Drug Development: Serves as a model for the development of advanced GLP-1 receptor agonists.
• Clinical Research: Extensively studied for its effects on both diabetes and obesity, with ongoing clinical trials.

Storage condition: Store in a cool, dry place, away from direct sunlight. Recommended storage temperature: -20°C.

Packing: Customized